Q3 2021 Financial Performance - Worldwide revenue reached $93.2 million, a decrease of 14% year-over-year and 7% compared to Q3 2019[5] - U S revenue was $78.1 million, also down 14% year-over-year and 7% from Q3 2019[5] - International revenue amounted to $15.2 million, a 14% decrease as reported or 16% decrease in constant currency compared to the previous year, and a 5% decrease as reported or 12% decrease in constant currency compared to Q3 2019[5] - Gross margin was 69 3%, a decrease of 0 8% year-over-year and 0 5% compared to Q3 2019[5] - Operating expenses totaled $91.1 million, a 14% increase year-over-year and 6% increase compared to Q3 2019, excluding a $20 million patent litigation judgement[5] - Adjusted EBITDA was negative $6 0 million, a 144% decrease year-over-year and 201% decrease compared to Q3 2019[5] Q4 2021 Guidance - Revenue is projected to be between $94 million and $98 million, representing an 11% to 14% decrease compared to Q4 2020, and a 14% to 18% decrease compared to Q4 2019[16] - Non-GAAP adjusted EBITDA is expected to be negative $10 million to negative $13 million[16] Peripheral Neuropathy (PDN) Opportunity - The annual total addressable market (TAM) for PDN is estimated to be approximately $3 5 billion to $5 0 billion[23] - Nevro is the only company with a specific on-label indication from the FDA for treating PDN[27] Non-Surgical Refractory Back Pain (NSRBP) Opportunity - The total addressable market for NSRBP is $7 5 billion, with current market penetration at only 4%, representing a $300 million market[29, 30]

Nevro Corp. (NYSE:NVRO) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Julie Dewey - Vice President-Investor Relations and Corporate Communications Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi Chris Pasquale - Guggenheim Tom Hopkins - Bank of America Robbie Marcus - JPMorgan Matt Taylor - UBS Daniel Antalffy - SVB Leerink David Rescott - Truist Security Suraj Kalia ...

Market Overview - The global spinal cord stimulation (SCS) market was approximately $2.5 billion pre-COVID-19, with the company aiming to expand its market share by treating both back and leg pain without paresthesia[95]. - The company has experienced significant revenue growth in the U.S. since the commercial launch of the Senza system in May 2015, with reimbursement from all major insurance providers[96]. - Revenue increased from $18.2 million in 2012 to $362.0 million in 2020, primarily driven by Senza sales in the U.S.[116]. Financial Performance - The company reported total sales revenue of $93.2 million for the nine months ended September 30, 2021, with U.S. sales contributing $237.8 million and international sales contributing $46.3 million[97]. - Revenue for the nine months ended September 30, 2021, increased to $284.1 million, a 13% rise from $252.3 million in the same period in 2020[144]. - Revenue decreased to $93.2 million in Q3 2021, down 14% from $108.5 million in Q3 2020[135]. - Gross profit fell to $64.6 million in Q3 2021, a decrease of 15% from $76.1 million in Q3 2020, with a gross margin of 69%[136]. - Gross profit for the nine months ended September 30, 2021, increased to $196.9 million, a 15% increase from $171.9 million in the same period in 2020[146]. - Total operating expenses for the nine months ended September 30, 2021, were $281.6 million, up 20% from $233.9 million in the same period in 2020[147]. - Operating expenses increased to $111.1 million in Q3 2021, up 39% from $79.6 million in Q3 2020[137]. - Interest income decreased to $0.6 million in the nine months ended September 30, 2021, down from $2.6 million in the same period in 2020[150]. - Net cash used in operating activities was $26.7 million for the nine months ended September 30, 2021, compared to $10.7 million for the same period in 2020, driven by net losses of $101.2 million[159]. Research and Development - The company has multiple clinical trials in progress, including studies for painful diabetic neuropathy (PDN) and non-surgical refractory back pain (NSRBP)[95]. - The company is investing in R&D to expand into new indications and improve product outcomes, with ongoing clinical trials for the 10 kHz Therapy[113]. - The company plans to continue investments in the development of the Senza product platform and 10 kHz Therapy for chronic pain treatment, alongside ongoing R&D programs and clinical trials[155]. Product and Market Strategy - The 10 kHz Therapy demonstrated nearly twice the success rate in treating back pain and 1.5 times the success rate in treating leg pain compared to traditional SCS therapy[95]. - The company received FDA approval for its 10 kHz Therapy for chronic intractable pain management in July 2021 and has initiated a commercial rollout[107]. - The company intends to continue investing in U.S. commercial infrastructure and research and development to support future regulatory submissions and product expansion[97]. - The company is focused on educating physicians about the advantages of its products, which is essential for revenue growth in a competitive market[106]. Operational Challenges - The COVID-19 pandemic has negatively impacted the number of Senza trials and permanent system implant procedures, affecting overall revenue and financial condition[101]. - The company does not expect to continue its historical revenue growth rates due to various factors, including the impact of the COVID-19 pandemic and reimbursement constraints in international markets[116][117]. - Medicare requires Prior Authorization for certain outpatient procedures, which may affect revenue growth due to potential negative coverage decisions by private insurers[109]. - The company has maintained high levels of inventory to support its product sales, which has significantly impacted cash used in operations[112]. - The average sales price of the Senza system varies geographically, affecting revenue from international sales due to currency fluctuations[121]. - Operating expenses include significant legal costs related to intellectual property litigations, which are expected to continue[130]. Financing and Commitments - The company issued $165.0 million in 2.75% convertible senior notes due 2025, with total net proceeds of approximately $183.6 million after deducting costs[98][99]. - The company may seek additional funding through equity or debt financings to support R&D, product expansion, or acquisitions, depending on various market factors[156]. - As of September 30, 2021, the company had minimum annual purchase commitments of $1.3 million due in the remainder of 2021[166]. - Contractual obligations include interest payments of $5.2 million annually from 2022 to 2024, and total payments of $192.4 million due in 2025 related to the 2025 Notes[168].

IIIIIIII nevro 2Q 2021 Earnings Presentation August 4, 2021 Forward-looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our third quarter financial guidance; our belief that there is a significant opportunity to offer our innovative therapy to PDN patients who are una ...

Nevro Corp. (NYSE:NVRO) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Julie Dewey – Vice President-Investor Relations and Corporate Communications Keith Grossman – Chairman, Chief Executive Officer and President Rod MacLeod – Chief Financial Officer Conference Call Participants Larry Biegelsen – Wells Fargo Bob Hopkins – Bank of America Robbie Marcus – JPMorgan Joanne Wuensch – Citi Matt Taylor – UBS Cecilia Furlong – Morgan Stanley Adam Maeder – Piper Sandler Chris Pasqual ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R.S ...

Financial Data and Key Metrics Changes - Nevro reported Q1 2021 worldwide revenue of $88.6 million, a 1% increase compared to Q1 2020 and an 8% increase compared to Q1 2019 [6][25] - U.S. sales were $74.7 million, a decrease of 1% year-over-year but an increase of 14% compared to Q1 2019 [6] - International revenue increased 14% year-over-year to $13.9 million, with a 4% increase on a constant currency basis [6] - Gross profit for Q1 2021 was $62.3 million, a 3% increase compared to the prior year [25] - Net loss from operations was $22.5 million, a 2% improvement compared to a loss of $23.1 million in the prior year [28] Business Line Data and Key Metrics Changes - U.S. permanent implant procedures remained flat year-over-year, while trial procedures declined by 4% [7] - Approximately 134 scheduled U.S. permanent implant procedures were canceled due to COVID, with 60% still unrecovered by the end of the quarter [8] - The company reported a record number of new patient leads from direct marketing efforts, indicating potential future growth [7] Market Data and Key Metrics Changes - The impact of COVID-19 on revenue and procedures lessened as the quarter progressed, with March showing encouraging improvement [7] - The company expects the U.S. market to recover more rapidly than international markets [7] Company Strategy and Development Direction - Nevro aims to launch its PDN (painful diabetic neuropathy) therapy in the second half of 2021, with a focus on generating awareness and expanding market access [10][13] - The company introduced a new brand identity, HFX, to unify its product offerings and enhance patient support [17] - The recent Omnia upgrade, HFX Connect, is expected to improve patient care and operational efficiency [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery from COVID-19 and the potential for increased patient demand for SCS therapy [9][23] - The company anticipates a gradual improvement in revenue and patient engagement as COVID-related restrictions ease [9][23] - Full-year 2021 revenue guidance was updated to approximately $440 million to $450 million, reflecting a 22% to 24% growth over the prior year [34] Other Important Information - Legal expenses related to patent litigation were $5.9 million for Q1 2021, significantly higher than the previous year [26] - The company published its first ESG report, highlighting its commitment to corporate responsibility [22] Q&A Session Summary Question: Current trialing perspective and Q2 guidance backlog conversion - Management noted that trialing improved in March, with expectations for continued improvement, but acknowledged that it is not yet at desired levels [42] Question: Size of the PDN sales force and payer coverage updates - The PDN sales force is expected to consist of 30 to 40 people, with ongoing efforts to engage payers for coverage decisions [44][48] Question: Percentage of payers expected to cover PDN by year-end - Management estimated that around 25% to 30% of total covered lives may have PDN coverage by the end of 2021, with expectations for growth in 2022 [51] Question: Omnia's market education and competitive positioning - Omnia currently accounts for 70% to 80% of total utilization, with management confident in its competitive advantages [54][56] Question: Guidance increase makeup - The guidance increase reflects optimism in core business recovery, market share capture, and contributions from PDN in the latter half of the year [58][60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R. ...

4Q and Full-Year 2020 Earnings Presentation 1 February 24, 2021 IIIIIIII neviro Forward-looking Statements | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Nevro Corp (NYSE:NVRO) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants Julie Dewey - VP, IR & Corporate Communications Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Participants Adam Maeder - Piper Sandler & Co. William Plovanic - Canaccord Genuity Robert Hopkins - Bank of America Merrill Lynch David Lewis - Morgan Stanley Allen Gong - JPMorgan Chase & Co. Danielle Antalffy - SVB Leerink Kaila Krum - Truist Securities Young Li - UBS Inve ...